Omar Siddiqi, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Cardiovascular Medicine

MD, Washington University School of Medicine
BS, University of Rhode Island

Pronouns: he/him/his



Omar Siddiqi, MD is an Assistant Professor of Medicine in Cardiovascular Medicine at the Chobanian and Avedisian School of Medicine, and he is the Program Director of the Cardiovascular Medicine Fellowship Program. As director of the cardiology fellowship curriculum, he is credited with developing an academic half day for cardiovascular medicine fellows, developing an echocardiography curriculum utilizing the CAE echocardiography simulator housed in the Solomont Simulation Center, and starting an Imaging Show and Tell conference. These efforts have been recognized with two Cardiovascular Medicine Fellowship Faculty Teaching Awards which he won in 2015 and 2018. At the Chobanian and Avedisian School of Medicine, he serves as co-director of the second year medical school cardiovascular pathophysiology module. His research interests in medical education include the development of simulation-based curricula and the integration of team-based learning (TBL) in teaching ECGs. His clinical interests include cardiac amyloidosis and echocardiography, and he is an attending cardiologist in the BU Amyloidosis Center. His clinical research interests are around the assessment of novel therapies for the treatment of cardiac amyloidosis. He has served as Clinical Investigator of five studies, including two currently.

Member
Boston University
Amyloidosis Center





ITL-2001-CL-301: MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
06/26/2024 - 06/26/2027 (PI)
Intellia Therapeutics, Inc.

AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participa
08/08/2022 - 08/08/2025 (PI)
Bristol-Myers Squibb Company

A Phase 2, randomized, placebo-controlled, subject and investigator blinded, multi-center study to assess the efficacy of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function
06/09/2020 - 06/09/2023 (PI)
Novartis Pharma Corp

Myocardial ischemia and Transfusion (MINT)-CCC
09/01/2016 - 05/31/2023 (Multi-PI)
PI: Omar Siddiqi, MD
Rutgers The State University of New Jersey NIH NHLBI
5U01HL133817-02


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Yurista S, Wadhera P, Eder RA, Elkayam U, Siddiqi OK. Peripartum HFpEF: Identification of a Novel Phenotype and the Need for Cardio-Obstetrics Management. JACC Adv. 2024 Feb; 3(2):100799. PMID: 38939402; PMCID: PMC11198047; DOI: 10.1016/j.jacadv.2023.100799;
     
  2. Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK, Ruberg FL, Sanchorawala V. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023 Oct 24; 7(20):6080-6091.View Related Profiles. PMID: 37581513; PMCID: PMC10582303; DOI: 10.1182/bloodadvances.2023010324;
     
  3. Hakim AD, Awili M, O'Neal HR, Siddiqi O, Jaffrani N, Lee R, Overcash JS, Chauffe A, Hammond TC, Patel B, Waters M, Criner GJ, Pachori A, Junge G, Levitch R, Watts J, Koo P, Sengupta T, Yu L, Kiffe M, Pinck A, Stein RR, Bendrick-Peart J, Jenkins J, Rowlands M, Waldron-Lynch F, Matthews J. Efficacy and safety of MAS825 (anti-IL-1ß/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function. Clin Exp Immunol. 2023 Oct 13; 213(3):265-275. PMID: 37338154; PMCID: PMC10570997; DOI: 10.1093/cei/uxad065;
     
  4. Rucker DM, Siddiqi OK, Pimentel DR, Luptak I. Hemodynamic testing to guide vasodilator therapy in cardiac amyloidosis. J Cardiol Cases. 2023 Sep; 28(3):105-108.View Related Profiles. PMID: 37671260; PMCID: PMC10477047; DOI: 10.1016/j.jccase.2023.04.011;
     
  5. Alreshq R, Cozzolino M, Lilleness B, Pipilas A, Mendelson L, Joshi T, Muralidhar V, Guardino E, Berk JL, Siddiqi OK, Gopal DM, Sanchorawala V, Ruberg FL. Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. Am J Cardiol. 2022 Oct 15; 181:105-112.View Related Profiles. PMID: 36028388; PMCID: PMC9675982; DOI: 10.1016/j.amjcard.2022.06.064;
     
  6. Schwartz B, Schou M, Ruberg FL, Rucker D, Choi J, Siddiqi O, Monahan K, Køber L, Gislason G, Torp-Pedersen C, Andersson C. Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study. JACC CardioOncol. 2022 Sep; 4(3):313-322.View Related Profiles. PMID: 36213365; PMCID: PMC9537076; DOI: 10.1016/j.jaccao.2022.05.009;
     
  7. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
     
  8. Prokaeva T, Joshi T, Klimtchuk ES, Gibson VM, Spencer B, Siddiqi O, Nedelkov D, Hu Y, Berk JL, Cuddy SAM, Dasari S, Chiu A, Choate LA, McPhail ED, Cui H, Chen H, Burks EJ, Sanchorawala V, Connors LH. A novel substitution of proline (P32L) destabilises ß2-microglobulin inducing hereditary systemic amyloidosis. Amyloid. 2022 Dec; 29(4):255-262.View Related Profiles. PMID: 35575118; DOI: 10.1080/13506129.2022.2072199;
     
  9. Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, Kataria S, Lohrmann G, Pipilas AR, Ruberg FL. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022 Jun; 29(2):71-78.View Related Profiles. PMID: 35083944; PMCID: PMC9258521; DOI: 10.1080/13506129.2021.2000388;
     
  10. Alreshq R, Tugal D, Siddiqi O, Ruberg F. Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. Pacing Clin Electrophysiol. 2021 Dec; 44(12):2092-2099.View Related Profiles. PMID: 34632598
     
Showing 10 of 30 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 30 publications over 15 distinct years, with a maximum of 5 publications in 2022

YearPublications
20051
20071
20091
20111
20121
20131
20151
20172
20183
20193
20204
20212
20225
20233
20241

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

Recent (within 3 months)

What to Know About Atrial Fibrillation in ATTR-CM

Everyday Health 9/19/2024
Older

Common Heart Medications Do Not Increase COVID-19 Risks, Studies Say

WBUR 5/4/2020

2019 Boston University School of Medicine: Faculty of the Month Award
2019 Boston University School of Medicine: Extra Miler Award
2018 Boston Medical Center: Cardiology Fellowship Teaching Award
2015 Boston Medical Center: Cardiology Fellowship Teaching Award
Contact for Mentoring:

88 E. Newton St Newton Pavilion
Boston MA 02118
Google Map

617.638.8760
Download vCard

Siddiqi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (129) concept(s)
_
Media Mentions
_
Co-Authors
See all (27) people
_
Similar People
See all (60) people
_
Same Department
Search Department